



# **Association between Maternal and Neonatal Vitamin D status and the Development of Congenital Anomalies**

*Thesis*

*Submitted for Partial Fulfillment of Master Degree in Pediatrics*

*By*

**Mohamed Mahmoud Ramadan Khalifa**

*M.B., B.Ch,*

*Faculty of Medicine - Shams University (2015)*

*Under supervision of*

**Prof. Dr. Mohamed Nasr El-Deen El-Barbary**

*Professor of Pediatrics*

*Faculty of Medicine, Ain Shams University*

**Prof.Dr./ Sahar Samir Abd El-Maksoud**

*Professor of Clinical Pathology*

*Faculty of Medicine, Ain Shams University*

**Dr. Suzan Abd El-Razek Mohamed**

*Lecturer of Pediatrics*

*Faculty of Medicine, Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

*2020*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قَالَ

سَبِّحْ اِنَّكَ لَا تَعْلَمُ لَنَا  
اِلَّا مَا عَلَّمْتَنَا اِنَّكَ اَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,  
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound  
gratitude to **Prof. Dr. Mohamed Masr El-Deen El-  
Barbary**, Professor of Pediatrics Faculty of Medicine, Ain  
Shams University for his keen guidance, kind supervision,  
valuable advice and continuous encouragement, which made  
possible the completion of this work.*

*I am deeply thankful to **Prof. Dr./ Sahar Samir  
Abd El-Maksoud**, Professor of Clinical Pathology Faculty of  
Medicine, Ain Shams University, for her great help, active  
participation and guidance.*

*I am also delighted to express my deepest gratitude and  
thanks to **Dr. Suzan Abd El-Razek Mohamed**, Lecturer  
of Pediatrics Faculty of Medicine, Ain Shams University, for her  
kind care, continuous supervision, valuable instructions,  
constant help and great assistance throughout this work.*

*Mohamed Khalifa*

# *List of Contents*

Title	Page No.
List of Tables .....	i
List of Figures .....	iii
List of Abbreviations.....	iv
Introduction .....	1
Aim of the Work.....	7
Review of Literature	
Vitamin D in Pregnancy .....	8
Congenital Anomalies .....	25
Vitamin D Deficiency and Adverse Fetal Outcomes .....	34
Patients and Methods.....	43
Results .....	48
Discussion .....	69
Summary and Conclusion.....	82
Recommendations .....	85
References .....	86
Arabic Summary .....	—

# *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Major congenital malformations .....	26
<b>Table (2):</b>	Minor congenital malformations.....	27
<b>Table (3):</b>	Comparison between patients group and control group regarding demographic data and maternal history .....	49
<b>Table (4):</b>	Comparison between patients group and control group regarding antenatal and neonatal history .....	50
<b>Table (5):</b>	Comparison between patients group and control group regarding vitamin D and calcium supplementation during pregnancy .....	51
<b>Table (6):</b>	Maternal and Neonatal vitamin D level in patient and control group. ....	52
<b>Table (7):</b>	Relation between maternal vitamin D status stratification with neonatal vitamin D status stratification .....	52
<b>Table (8):</b>	Correlation of maternal vitamin D level with neonatal vitamin D level in patients group. ....	55
<b>Table (9):</b>	Comparison between patients group and control group regarding maternal and neonatal vitamin D status stratification. ....	56
<b>Table (10):</b>	Category of congenital anomalies in group 1a .....	58
<b>Table (11):</b>	Subtypes of congenital anomalies in group 1a.....	58
<b>Table (12):</b>	Relation between maternal and neonatal vitamin D level with type of Congenital Anomaly.....	60
<b>Table (13):</b>	Relation between maternal vitamin D Category with neonatal type of congenital anomaly .....	61

## *List of Tables Cont...*

Table No.	Title	Page No.
<b>Table (14):</b>	Correlation of maternal vitamin D level with maternal age, total number of births and neonatal birth weight.....	62
<b>Table (15):</b>	Correlation of neonatal vitamin D level with maternal age, birth weight and order of birth. ....	63
<b>Table (16):</b>	Relation between maternal and neonatal vitamin D level with antenatal and neonatal history in group 1_1a.....	65
<b>Table (17):</b>	Relation between maternal vitamin D status stratification with antenatal and neonatal history in group 1 .....	66
<b>Table (18):</b>	Relation between maternal vitamin D stratification with vitamin D and calcium supplementation during pregnancy .....	67
<b>Table (19):</b>	Relation between maternal vitamin D status stratification with antenatal care follow up and neonatal history .....	68

# *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Vitamin D metabolism in the liver, 25-hydroxylation of vitamin D occurs leading to 25(OH)D .....	9
<b>Figure (2):</b>	Vitamin D metabolic pathways during pregnancy across maternal, fetal and placental compartments.....	12
<b>Figure (3):</b>	Diseases and conditions associated with maternal vitamin D deficiency .....	19
<b>Figure (4):</b>	Model of <i>in utero</i> VDD-induced epigenetic effects on long-term health outcomes in offspring.....	42
<b>Figure (5):</b>	Maternal and neonatal vitamin D level in patients group (1 and 1a).....	53
<b>Figure (6):</b>	Maternal and neonatal vitamin D level in control group (2 and 2a) .....	54
<b>Figure (7):</b>	Comparison between patients group and control group regarding maternal vitamin D status stratification. ....	57
<b>Figure (8):</b>	Comparison between patients group and control group regarding neonatal vitamin D status stratification .....	57
<b>Figure (9):</b>	Category of congenital anomalies in group 1a.....	59
<b>Figure (10):</b>	Correlation of maternal vitamin D level with birth weight.....	62
<b>Figure (11):</b>	Correlation of neonatal vitamin D level with order of birth. ....	64
<b>Figure (12):</b>	Correlation of neonatal vitamin D level with birth weight.....	64

## *List of Abbreviations*

Abb.	Full term
1,25-DHCC .....	1,25- dihydroxycholecalciferol
25OHD.....	25 hydroxyvitamin D
Ca.....	<u>C</u> alcium
CAs .....	Congenital anomalies
CHD .....	<u>C</u> ongenital heart disease
CNS .....	<u>C</u> entral nervous system
C-section .....	Cesarean section
CT .....	<u>C</u> omputed tomography
DOHaD.....	<u>D</u> evelopmental origins of health and disease
GDM .....	<u>G</u> estational diabetes mellitus
HATs.....	Histone acetyl transferases
HDACs.....	<u>H</u> istone deacetylases
IOM.....	Institute of medicine
MRI.....	<u>M</u> agnetic resonance imaging
NTDs .....	<u>N</u> eural tube defect
P .....	<u>P</u> hosphorus
PTH .....	<u>P</u> arathyroid hormone
PTHrP .....	PTH-related peptide
RCTs .....	Randomized Clinical Trials
RXR .....	<u>R</u> etinoid X receptor
SGA.....	<u>S</u> mall for gestational age
VACTERL .....	<u>V</u> ertebral anomalies, anal atresia, cardiac defects, trachea-esophageal fistula, renal anomalies, limb defects
VDR.....	<u>V</u> itamin D receptor
VDRE.....	<u>V</u> itamin D response element



# INTRODUCTION

**C**ongenital anomalies (CAs), also known as congenital malformations or birth defects, can be defined as functional or structural anomalies that occur during intrauterine life (*Elghanmi et al., 2020*).

Its etiology is unknown in 50% of cases and genetic in 30-40% and environmental in 5-10%. Medications, infectious agents, and environmental toxins had all been implicated as teratogens (*Onankpa et al., 2014*).

Vitamin D is not only a lipid-soluble vitamin, but also a steroid hormone that can be synthesized endogenously. It has an important role in calcium (Ca)-phosphorus (P) homeostasis (*Holick et al., 2016*).

Molecular and genetic studies confirm that vitamin D also has role in epigenetic modification and it modulates the risks of several other human diseases, including autoimmune disorders (*Zeitelhofer et al., 2017*).

Epigenetic modifications are among the most important mechanisms by which environmental factors can influence early cellular differentiation and create new phenotypic traits during pregnancy and within the neonatal period without altering the deoxyribonucleic acid sequence. Epigenetic changes can not only modulate the individual adaptation to the

environment but also have an influence on lifelong health and disease (*Indrio et al., 2017*).

Vitamin D regulates the essential pathways of cellular metabolism and differentiation via its nuclear receptor (vitamin D receptor) (VDR). In addition to this, vitamin D markedly influences the regulation of cell replication (*Karlic et al., 2011*).

Vitamin D deficiency in pregnancy has been found to be associated with development of multiple congenital anomalies in offspring in several studies, like congenital heart disease, congenital neural tube defect, congenital diaphragmatic hernia (*Kim et al., 2016*).

Thus, it is advisable to review Vitamin D deficiency in mothers and their offspring so that strategies can be implemented to prevent the impact of vitamin D deficiency on the fetus.

## **AIM OF THE WORK**

**T**his study aims to evaluate the potential association between maternal and neonatal vitamin D status and the subsequent development of congenital anomalies.

## Chapter One

# VITAMIN D IN PREGNANCY


## Physiology of vitamin D

Vitamin D is a fat-soluble vitamin with two major physiological forms: Ergocalciferol, (vitamin D<sub>2</sub>) and Cholecalciferol (vitamin D<sub>3</sub>) (*DeLuca, 2014*). These two forms basically differ in their side chain structure, While D<sub>2</sub> is mainly obtained from plants and vegetable sources, D<sub>3</sub> is majorly synthesized in the skin on exposure to sunlight (UVB radiation) from 7 dehydrocholesterol, Both forms of vitamin D are also available as dietary supplements (*De-Regil et al., 2016*).

All the forms of vitamin D are activated only on enzyme-mediated hydroxylation.

The first hydroxylation reaction is mediated by 25 $\alpha$ -hydroxylase, to produce 25 hydroxyvitamin D (25OHD) or calcidiol and takes place in the liver, This is followed by the next hydroxylation step in the kidney, mediated by 1 $\alpha$ -hydroxylase, to produce 1,25- dihydroxycholecalciferol (1,25-DHCC) or calcitriol (*Harvey et al., 2014*). (**Figure 1**)

While 25OHD is the most abundant circulating form of vitamin D, 1,25-DHCC is the most active form. The hydroxylation reactions and the availability of active vitamin D are regulated by serum calcium and phosphorus and parathyroid hormone (PTH) (*Sahota, 2014*).



**Figure (1):** Vitamin D metabolism in the liver, 25-hydroxylation of vitamin D occurs leading to 25(OH)D. In the kidney, a second hydroxylation takes place by 1  $\alpha$ -hydroxylase leading to the formation of 1,25-dihydroxyvitamin 2D, the biologically active form of vitamin D (Holick *et al.*, 2006).

### Dietatic sources of vitamin D (Dawodu *et al.*, 2013).

Vitamin D is also found in a number of foods:

- Oily fish – such as salmon, sardines and mackerel
- Red meat
- Liver and beef
- Milk
- Egg yolks
- Fortified foods – such as some fat spreads and breakfast cereals

Vitamin D is a secosteroid, which is also considered an important prohormone (Weinert *et al.*, 2015). Since vitamin D receptors (VDRs) are present in many cells and tissues throughout the body, many studies support the role of vitamin D in several physiological functions beyond bone and muscle

health (*Joergensen et al., 2014*). During pregnancy, vitamin D plays a vital role in embryogenesis, especially fetal skeletal development and calcium homeostasis (*Hollis et al., 2011*).

Several studies suggested the increasing prevalence of vitamin D deficiency in pregnancy and the associated adverse maternal and fetal outcomes, such as gestational diabetes mellitus (GDM), preeclampsia, small for gestational age (SGA) and preterm births (*Palaniswamy et al., 2016*).

### **Vitamin D physiology during pregnancy**

During pregnancy, mobilization of maternal calcium increases to meet the demands of adequate fetal bone mineralization (*Olmos-Ortiz et al., 2015*). As a consequence, a number of physiological adaptations take place, including increased maternal serum calcitriol, vitamin D binding protein (DBP) and placental VDR activity to maintain normal serum levels of 25OHD and calcium (*Olmos-Ortiz et al., 2015*).

Besides the kidneys, the placenta can potentially activate 25(OH) D, since it contains the enzyme 1- $\alpha$ -hydroxylase producing 1, 25(OH) 2D. Moreover, placenta has a paracrine control of vitamin D metabolism and it may also inactivate 25(OH)D by 24-hydroxylation to 24,25(OH)2D. This makes it possible for a local regulation of vitamin D levels within the placental tissue that may modulate anti-inflammatory effects

and affect pregnancy development and/or perinatal outcomes (*Liu et al., 2012*) (*Fig. 2*).

Plasma levels of 1.25 (OH) 2D increases in early pregnancy, reaching a peak in the third trimester and returning to normal during lactation. A potent stimulus to placental transfer of calcium and placental synthesis of vitamin D is the PTH-related peptide (PTHrP), produced in the fetal parathyroid and placental tissues, which increases the synthesis of vitamin D. The PTHrP can reach the maternal circulation and it acts through the PTH/PTHrP receptor in the kidney and bones, being a mediator in the increase of 1.25(OH) 2D and helping in the regulation of calcium and PTH levels in pregnancy.

Other signals involved in the regulation process include prolactin and the placental lactogen hormone, which increase intestinal calcium absorption, reduce urinary calcium excretion and stimulate the production of PTHrP and 1.25(OH) 2D (*Mulligan et al., 2010*).